First US startup with a licensed pathway to purpose-built small radioisotope reactors (VIPR); acquired by Oklo (NYSE: OKLO) in Feb 2025 in a ~$28.4M all-stock deal, giving StoryHouse a public equity position with material mark-to-market upside. First-mover with an NRC construction permit application in review for a purpose-built isotope reactor (VIPR), DOE Reactor Pilot Program selection, INL site tenancy, and integration with Oklo's fuel-cycle and reactor engineering capabilities — near-impossible for a new entrant to replicate inside 5+ years.
Current state: Atomic Alchemy was acquired by Oklo (NYSE: OKLO) on Feb 28, 2025 for ~$28.4M all-stock (announced as ~$25M), and now operates as Oklo's radioisotope subsidiary building the Groves VIPR pilot reactor in Texas (targeting July 2026 criticality) and a commercial isotope facility at Idaho National Laboratory.
Supply-constrained bottleneck market with structural scarcity for Ac-225 and reliable Mo-99 — buyers (Novartis, Lilly, Bayer, BMS) paying premiums to secure supply.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Atomic Alchemy | Only US-based startup with a licensed pathway to purpose-built, small non-power reactors (VIPR) producing 40+ radioisotopes including Mo-99, Ac-225, Cu-67, Lu-177 for radiopharma customers. | Seed II / SH entry 2020-08-24 | — |
| NorthStar Medical Radioisotopes | Domestic non-uranium Mo-99 and Ac-225 producer | $250M+ raised; private Web | Already commercial-scale Mo-99; further along on Ac-225 |
| SHINE Technologies | Accelerator-based Mo-99 and Lu-177 producer | >$1B raised Web | Larger scale, accelerator (non-reactor) tech avoids NRC reactor risk |
| BWX Technologies (BWXT) | Public defense/medical isotope conglomerate | Public, ~$8B mkt cap Web | Existing nuclear infrastructure, defense customer base, cash to outspend |
| Curium Pharma | Global leader in SPECT/PET diagnostic isotopes | PE-backed (CapVest) Web | Vertical from isotope through drug product |
Moat: First-mover with an NRC construction permit application in review for a purpose-built isotope reactor (VIPR), DOE Reactor Pilot Program selection, INL site tenancy, and integration with Oklo's fuel-cycle and reactor engineering capabilities — near-impossible for a new entrant to replicate inside 5+ years.
StoryHouse's $1M at $9M post ≈ 11.1% pre-dilution → allocation ~$3.1M of the $28.4M deal (~3.1x undiluted; ~2-2.5x post-dilution). Mark-to-market on OKLO stock could be materially higher — OKLO's June 2025 raise netted $442M at premium prices; potentially 8-15x depending on when shares can be sold
Likely acquirers: Oklo (completed).
Comparable exits: Lantheus / Evergreen Theragnostics 2025 · Novartis / Point Biopharma $1.4B 2023 · BMS / RayzeBio $4.1B 2023.